Tranexamic acid body lotion sold in the United States does not require pre-market FDA approval when it is positioned and labeled as a cosmetic. Cosmetics in the US are regulated under the Federal Food, Drug, and Cosmetic Act and, since 2023, under the Modernization of Cosmetics Regulation Act (MoCRA) — neither of which requires pre-market approval. However, there are important compliance requirements and a critical classification boundary that every brand owner must understand.
Under MoCRA, effective for most brands by July 2024, you must (1) register your manufacturing or processing facility with the FDA and (2) submit a product listing for each cosmetic product you introduce to the US market. These are not approvals — the FDA does not review or sign off on the formulas — but failure to comply is a prohibited act that can result in Warning Letters, import alerts, or product recalls. Your contract manufacturer may handle facility registration on their end, but product listing is the brand owner's responsibility.
The classification line to watch: if your marketing language implies that the lotion treats, cures, or prevents a disease or alters a physiological function, FDA may deem it a drug rather than a cosmetic. For TXA body lotions, safe cosmetic claim territory includes phrases like "helps reduce the appearance of dark spots," "evens skin tone," and "visibly brightens." Problematic language includes "treats hyperpigmentation," "inhibits melanin production" (mechanistic drug-like claim), or any reference to a medical condition. Your cosmetic chemist and a regulatory consultant should review all label and marketing copy before launch.
For the EU, the regulatory framework is stricter. Tranexamic acid is not currently on the EU Cosmetics Regulation Annex III (restricted substances) or Annex II (prohibited substances) list, meaning it is permissible but must be substantiated for safety by a qualified cosmetic safety assessor in a Product Information File. A Responsible Person must be appointed within the EU, and the product must be notified through the CPNP before it goes on sale. Your EU-market lotion must also carry a Period After Opening (PAO) symbol and full EU-compliant labeling.
For Canada (Health Canada), TXA in cosmetics falls under the Cosmetics Regulations; a Cosmetic Notification must be filed within 10 days of first sale. For the UK post-Brexit, the UK Cosmetics Regulation (retained EU law) applies, requiring a separate UK Responsible Person and SCPN notification.
The safest path is to work with a contract manufacturer experienced in multi-market regulatory compliance. AJ Cosmo Labs' vetted manufacturer network includes suppliers who can guide you through MoCRA listing, EU CPNP notification, and Health Canada filing simultaneously. Download the app to connect with manufacturers who have cross-market compliance experience.
Ingredients in this answer: Tranexamic Acid
Read the full guide on Private Label Tranexamic Acid Body Lotion Manufacturer →